Genetic engineering concept. Medical science. Scientific Laboratory.
image-

APDN Subsidiary, LineaRx, Inc., Sign Licensing Agreement with LifeSensors

Posted on

STONY BROOK N.Y., January 13, 2020 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics and cancer diagnostics, has signed a licensing agreement with LifeSensors, Inc. (“LifeSensors”), to incorporate LifeSensors’ high expression SUMO-fusion technologies into the Company’s linear DNA […]

Read More email

image-

Applied DNA Sciences Reports 14 Development Customers for its Linear DNA Manufacturing Platform

Posted on

STONY BROOK, N.Y., November 25, 2019 –  Applied DNA Sciences, Inc. (NASDAQ: APDN, Applied DNA, “the Company”) announced today that LineaRx, Inc., its majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has grown its customer base to fourteen companies currently testing its linear DNA manufacturing platform for the development of nucleic acid-based therapies and diagnostics.  The Company […]

Read More email

image-

iCTC Platform Shows Superior Correlation over PSA as a Biomarker

Posted on

STONY BROOK, N.Y., October 1, 2019 – LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its invasive Circulating Tumor Cells (iCTCs) platform demonstrated superior correlation over Prostate Specific Antigen (PSA) in an ongoing Phase II trial in recurrent prostate cancer. Most notably, the concentration of rare iCTCs […]

Read More email

image-

Medicare Coverage of CAR T-Cell Therapy Holds Positive Implications for LineaRx

Posted on

STONY BROOK, NY. August 12, 2019 – LineaRx, Inc. (“LineaRx”), a majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced that, in a decision rendered on August 7, 2019, the Centers for Medicare and Medicaid Services (CMS) approved chimeric antigen receptor (CAR) T-cell therapies that fit the CMS criteria […]

Read More email

image-

LineaRx Acquires Assets and Intellectual Property of Vitatex

Posted on

STONY BROOK, NY. August 8, 2017 – LineaRx, Inc. (“LineaRx”), a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ: APDN), announced today that it has acquired the physical assets and Intellectual Property (IP) of Vitatex Inc. (“Vitatex”), a private biotechnology company focused on advancing personalized medicine with an innovative solution […]

Read More email

image-

LineaRx Receives Multiple Orders for Linear DNA for Use in Therapeutic Development

Posted on

STONY BROOK, NY. July 1, 2019 – LineaRx, Inc., a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ: APDN), announced today that it has received multiple purchase orders, from several major developers of gene and cell therapies, for its proprietary and patented large-scale, polymerase-chain-reaction (PCR)-produced linear DNA. LineaRx believes this […]

Read More email

image-

LineaRx Anticipates Expansion in Diagnostics Market

Posted on

STONY BROOK, NY. May 21, 2019 – LineaRx, a wholly-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), announced that it is in process of designing new, custom amplicons for an existing customer in the in vitro diagnostics market. The diagnostic assay is expected to be available and qualified in 2020, potentially resulting in increasing […]

Read More email

image-

LineaRx Achieves Higher Expression and Survival Rates in Human T Cells

Posted on

STONY BROOK, NY. April 29, 2019 – LineaRx, Inc. ( the “Company”) a wholly owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today that it has improved expression levels and survival rates of linear DNA constructs delivered without viruses or plasmids to human T cells. In collaboration with Avectas, a cell engineering technology […]

Read More email

image-

LineaRx Achieves Anti-CD19 Expression in Human CAR T Cells via Plasmid-Free Platform

Posted on

STONY BROOK N.Y., April 8, 2019 – Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that LineaRx, (the “Company”), its subsidiary focused on next-generation biotherapeutics, has achieved anti-CD-19 CAR (Chimeric Antigen Receptor) expression in human T Cells via its proprietary, non-viral, plasmid-free (NVPF) manufacturing platform. To the Company’s knowledge, this seminal event represents the first […]

Read More email

image-

LineaRx to Announce DNA Vaccine Preclinical Data and Efficacy of In-Licensed CAR T Therapy

Posted on

[vc_column_text el_class=”graphic”]STONY BROOK N.Y., December 4, 2018 – LineaRx, Inc., the biotherapeutics company based on the use of large-scale production of gene-sized DNA by Polymerase Chain Reaction (“PCR”) and dedicated to revolutionizing biotherapeutics for the masses in affordability, availability, time-to-market, and reducing the risk associated with virally mediated therapy, and a wholly-owned subsidiary of Applied […]

Read More email

image-

LineaRx Provides Cost and Quality Advantages to Technogenetics

Posted on

STONY BROOK, NY. November  7, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”  or the “Company”) has been providing linear DNA to Technogenetics (Shanghai Kehua Bio-Engineering Co., Ltd-KHB group) that produces and sells kits to detect autoimmunity and infectious diseases. […]

Read More email

image-

At LineaRX, Putting The Horsepower Behind The CAR T

Posted on

[vc_single_image image=”15087″ img_size=”large”] Unique position: With its next-level ability to produce DNA constructs, Stony Brook startup LineaRX is looking to speed up production of critical, anti-cancer chimeric antigen receptor modified T cell (or CAR T) therapies. By GREGORY ZELLER //OCTOBER 16, 2018 Marking a big step in the war against cancer, a Stony Brook-based startup […]

Read More email

image-

LineaRx Licenses CAR T Drug Candidate, Initiates Pre-Clinical Development of Non-viral, Plasmid-free CAR T Manufacturing Platform

Posted on

STONY BROOK, N.Y., October, 16, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has initiated pre-clinical development of a non-viral, plasmid-free (NVPF) chimeric antigen receptor (CAR) modified T cell (CAR […]

Read More email

image-

LineaRx Secures New RNA Therapeutics Customers for Contract Research Services

Posted on

STONY BROOK N.Y., October 1, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA), the leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx” ” or the “Company”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has secured multiple new developers of RNA therapeutics as customers for its Contract Research Organization (CRO) […]

Read More email

image-

With New Spinoff, Biotech Goes All-In On DNA Sales

Posted on

[vc_single_image image=”16463″ img_size=”large”]Chain reaction: With an eye on exploding biotherapeutic fields, Stony Brook-based Applied DNA Sciences has spun its DNA-manufacturing business into a new company, LineaRx.

Read More email

image-

APDN Forms Subsidiary, LineaRx, to Develop DNA for Biotherapeutics

Posted on

STONY BROOK N.Y., September 18, 2018 – Applied DNA Sciences Inc., (NASDAQ: APDN, “Applied DNA” or the “Company”), the leader in large-scale PCR-based DNA manufacturing, announced today the formation of LineaRx, Inc., a wholly owned subsidiary. Its purpose is to commercialize the Company’s extensive experience in the design, manufacture and chemical modification of DNA by […]

Read More email